Oxygen Biotherapeutics is
now Tenax Therapeutics
Tenax Therapeutics is focused on developing and commercializing pharmaceutical products that improve outcomes for critical care patients.In the U.S. alone, more than five million hospitalized patients are treated in an intensive care setting annually according to the Society of Critical Medicine (www.sccm.org).
Focus on Critical CareGiven the high mortality, morbidity, and costs associated with the treatment of many intensive care patients, we believe that there is a substantial opportunity to add value for patients, physicians, hospitals, and ultimately shareholders.
Sep 24 2014 Tenax Therapeutics Announces First Quarter Fiscal Year 2015 Financial Results Sep 22 2014 Tenax Therapeutics Announces First Patients Enrolled in Phase 3 LEVO-CTS Clinical Trial of Levosimendan Sep 19 2014 Tenax Therapeutics to Provide Corporate Update and Discuss First Quarter Fiscal Year 2015 Financial Results on September 24, 2014